02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
01:42 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Tamura reclaims CEO role at Sosei

Sosei Group Corp. (Tokyo:4565) said Peter Bains will step down as president and CEO and resign as director on Dec. 31. Executive Chairman, founder and former CEO Shinichi Tamura will replace Bains, effective Jan. 1....
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
02:27 , May 25, 2018 |  BC Extra  |  Financial News

Anti-infectives play Iterum raises $80M in IPO

Iterum Therapeutics plc (NASDAQ:ITRM) raised $80 million late Thursday through the sale of 6.2 million shares at $13 in an IPO underwritten by Leerink, RBC Capital Markets, Guggenheim and Needham. The price values Iterum at...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
19:13 , May 18, 2018 |  BC Week In Review  |  Financial News

Iterum sets IPO range

Antibiotics company Iterum Therapeutics plc (Dublin, Ireland) amended its proposed IPO on NASDAQ on May 16 and now plans to sell 5.3 million shares at $14-$16. At the $15 midpoint, the company would raise $80...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
15:25 , Feb 23, 2018 |  BC Week In Review  |  Company News

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix declined to disclose further details about...
23:28 , Feb 21, 2018 |  BC Extra  |  Company News

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix said it could not provide details...
23:53 , Feb 20, 2018 |  BC Extra  |  Company News

Management tracks: Cell Medica, Iterum

Cancer immunotherapy company Cell Medica Ltd. (London, U.K.) appointed Kevin Boyle as CFO. He was CFO at FloWorks International LLC (Houston, Texas). Anti-infectives company Iterum Therapeutics Ltd. (Dublin, Ireland) hired Jeff Schaffnit as chief commercial...